Analyzing Synaptogenix (TAOX) & Its Peers

Synaptogenix (NASDAQ:TAOX) is one of 452 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its rivals? We will compare Synaptogenix to related companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, analyst recommendations and earnings.

Risk and Volatility

Synaptogenix has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Synaptogenix’s rivals have a beta of 10.25, meaning that their average stock price is 925% more volatile than the S&P 500.

Valuation & Earnings

This table compares Synaptogenix and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Synaptogenix	$3,962.00	-$12.77 million	-0.40
Synaptogenix Competitors	$439.11 million	-$68.88 million	-9.51

Synaptogenix’s rivals have higher revenue, but lower earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and price targets for Synaptogenix and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Synaptogenix Competitors	4793	9962	16002	371	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 113.31%. Given Synaptogenix’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Synaptogenix has less favorable growth aspects than its rivals.

Profitability

This table compares Synaptogenix and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-277.76%	-150.79%
Synaptogenix Competitors	-2,625.49%	-359.63%	-43.39%

Institutional and Insider Ownership

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Synaptogenix rivals beat Synaptogenix on 9 of the 13 factors compared.

Synaptogenix Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.